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ABSTRACT
Background: Unlike other solid tumors (i.e. pancreas, gallbladder, stomach), an ovarian cancer is responsive to a systemic 
treatment with platinum derivates in 80% of patients. This apparent chemosensitivity justifies a broader surgical approach. 
A cytoreductive, ”tumor-debulking” surgery is defined as an attempt to remove in a maximum degree all visible and detect-
able lesions. Despite treatment, the advancement of the disease very often leads to complications defined as “surgical” 
and life-threatening.
Objectives: The aim was to evaluate the efficacy and safety of palliative surgery in advanced ovarian cancer implicating 
acute surgical diseases of the abdominal cavity.
Material and methods: Between years 2005 and 2014 were operated 118 patients with an advanced ovarian cancer (FIGO 
III-IV) implicating acute and directly life-threatening diseases of the abdominal cavity, involving 132 surgical operations. The 
causes of these operations were: obstruction of the gastrointestinal tract — 91 patients; perforation of the gastrointestinal 
tract — 15; gastrointestinal bleeding — 9; intussusceptions — 3. 
Results: Retrospective data for the 118 patients were analyzed. Safety and the perioperative mortality rate were assessed. 
Serious postoperative complications were recorded in 31 patients (anastomotic stoma — 9; bleeding requiring repeated 
surgery —3; recurring gastrointestinal obstruction — 16; liver failure after partial hepatic resection — 3). Systemic compli-
cations in the form of respiratory failure and cardiovascular disorders requiring cardiological treatment — 21. All patients 
required clinical nutrition, both parenteral and enteral. Deaths recorded — 3. 39 patients were rehospitalized within 30 days 
of surgery. 7 deaths were recorded in this group. 
Conclusions: Combining lifesaving surgery with cytoreduction allows further adjuvant treatment. Early rehospitalization 
occurring within less than 30 days is linked to increased mortality.
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INTRODUCTION 
Knowledge about epithelial ovarian cancer (EOC) con-
tinuously widened in the last few decades. New theories 
and discoveries concerning its true origin and particular 
histological features cast light on EOC’s real nature and 
behavior. The studies aimed to define optimal therapeutic 
procedures.
While many issues remain unresolved, like an optimal 
time to perform a primary cytoreductive surgery, the advan-
tages resulting from administered drugs, the development 
of the disease’s early detection or even prevention schemes, 
it is the value of an optimal tumor resection defined by the 
intensity of the minimal residual disease’s relapse that enjoys 
a well-established position in numerous prospective and ret-
rospective studies. We may read in these studies, that a radical 
resection of a tumor has a decisive prognostic significance, 
even in the case of unfavorable factors, such as peritoneal 
metastasis. While many works exist on the subject of second-
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ary surgical cytoreduction with subsequent chemotherapy, 
there is a lack of works about cytoreductive surgery in pa-
tients undergoing a third or fourth operation complicated by 
an acute disease of the abdominal cavity. There is only one 
analysis regarding 15 patients qualified for a quaternary cy-
toreductive surgery (Memorial Sloan-Kettering Cancer Center 
(Shih et al., 2010).) The study analyzed the results of surgical 
treatment and attempted to define the patients for whom 
such surgery is indicated. In 1983, Berek et al. introduced for 
the first time the term “secondary cytoreduction”. According 
to most physicians, this is a surgical procedure performed 
after the completion of basic therapy and intended to re-
duce the mass of the tumor. This type of surgery aims to 
improve the patient’s quality of life as a result of an elimina-
tion of symptoms due to the presence of the tumor. These 
are non-healing procedures and original studies concerning 
patients displaying a sub-optimal response to treatment 
showed only marginal advantages, with a median survival 
of 9 months [6, 22]. Thus, no proof exists at present that sec-
ondary surgery constitutes a real advantage for this popula-
tion of patients. Ovarian carcinoma increasingly becomes 
a long-term disease and the issues concerning its treatment 
at a severely advanced stage involve complications in need 
of acute care surgery of the abdominal cavity. The useful-
ness of such procedure was called into question in the case 
of a selected group of patients, when it appeared that after 
the elimination of the cause of a gastrointestinal obstruction 
and the removal of a large and poorly vascularized tumorous 
mass, the patients began once again to respond well to the 
adjuvant treatment. A surgical justification for the elimination 
of the cause, like an obstruction, but also for the removal of 
the tumor, is a reinforcement of the immune system due to 
the reduction of the tumor’s mass. 
MATERIAL AND METHODS
118 patients operated between 2005 and 2014 because 
of an ovarian carcinoma implicating an acute abdominal 
cavity disease. Demographic data are presented in Table 1.
RESULTS 
Retrospective data for 118 patients were analyzed. 
Safety and mortality during the perioperative period were 
assessed. Severe surgical postoperative complications were 
observed in 31 patients [anastomosis — 9; bleeding requir-
ing new surgery — 3; recurrence of gastrointestinal obstruc-
tion — 16; pancreatitis after partial resection — 3 (Tab. 2)]. 
Systemic complications like respiratory failure and 
cardiovascular disorders requiring cardiologic treatment 
— 21 (Tab. 3). All patients required parenteral, as well as 
enteral nutrition. Were recorded 3 deaths. 
39 patients were rehospitalized within 30 days of sur-
gery. In this group were recorded 7 deaths. T
ab
le
 1
. D
em
og
ra
ph
ic
 d
at
a,
 ca
us
e 
an
d 
ty
pe
 o
f p
er
fo
rm
ed
 su
rg
er
y
13
2 
op
er
at
io
ns
Ag
e 
42
–8
1 
(6
9)
in
di
ca
tio
ns
 fo
r s
ur
ge
ry
Tr
ea
tm
en
t h
is
to
ry
 
Ty
pe
 o
f a
cu
te
 ca
re
 su
rg
er
y 
Pa
re
nt
er
al
 n
ut
rit
io
n
En
te
ra
l n
ut
rit
io
n 
M
et
as
ta
si
s 
re
se
ct
io
n 
Ra
di
ca
lit
y 
of
 re
se
ct
io
n
R 
= 
0
R 
< 
1
R 
> 
1
Po
st
op
er
at
iv
e 
ch
em
ot
he
ra
py
 
N
 —
 1
18
G
as
tro
in
te
st
in
al
 o
bs
tr
uc
tio
n 
(9
1)
Pr
im
ar
y 
su
rg
er
y 
(7
8)
Ch
em
ot
he
ra
py
 (9
1)
He
m
ic
ol
ec
to
m
y 
P 
(1
3)
He
m
ic
ol
ec
to
m
y 
L 
(3
7)
Si
gm
oi
d 
co
le
ct
om
y 
(1
9)
An
te
rio
r r
es
ec
tio
n 
AR
 (2
2)
29
62
91
R 
> 
1–
91
74
 p
at
ie
nt
s
G
as
tro
in
te
st
in
al
 p
er
fo
ra
tio
n 
(1
3)
Pr
im
ar
y 
su
rg
er
y 
(1
3)
Ch
em
ot
he
ra
py
 (1
3)
St
om
ac
h 
re
se
ct
io
n 
BI
 (2
)
St
om
ac
h 
re
se
ct
io
n 
BI
I (
1)
Sm
al
l b
ow
el
 re
se
ct
io
n 
(1
0)
13
0
13
R 
> 
1 
13
10
G
as
tro
in
te
st
in
al
 b
le
ed
in
g 
(9
)
Ch
em
ot
he
ra
py
 (9
)
Se
ct
io
na
l c
ol
ec
to
m
y 
(7
)
Sm
al
l b
ow
el
 se
ct
io
na
l r
es
ec
tio
n 
(2
)
9
0
3
R 
> 
1 
9
6
In
tu
ss
us
ce
pt
io
n 
(3
)
Ch
em
ot
he
ra
py
 (3
)
Si
gm
oi
d 
re
se
ct
io
n 
(1
)
Sm
al
l b
ow
el
 re
se
ct
io
n 
(2
)
3
0
3
R 
> 
1 
3
3
687
Tomasz Miłek et al., Evaluation of urgent multivisceral resections due to complications resulting from an advanced ovarian cancer
www. journals.viamedica.pl/ginekologia_polska
With postoperative surgeon’s control 89 patients were 
embraced (72.9%). Within 30 days after the surgery 39 pa-
tients were rehospitalized due to surgical complications 
(33%). Despite intensive treatment, surgical and nutritional 
7 patients (aged between 60 and 79) died. For the adjuvant 
treatment 71 patients from the group under control were 
classified. They were divided into two parts depending on 
age. The first group consisted of patients up to 50 years of 
age and the second one above 50 years of age. To the first 
group 18 patients were qualified. After a year observation 
there was no mortality in this group. In the second group 
there were 53 patients. In this group we observed the an-
nual survival in 31 patients. Annual mortality in the group 
receiving the adjuvant therapy was 31%.
DISCUSSION 
An analysis of data from 53 studies involving 6885 pa-
tients with a n epithelial ovarian carcinoma who were op-
erated to obtain the greatest degree of cytoreduction of 
lesions and subsequently treated systematically shows, that 
cytoreduction is an independent prognostic factor related to 
the rate of survival [1–3]. Each 10% increase in tumor mass 
reduction meant a 5.5% increase of the survival median. Cur-
rent studies confirm, that an optimal surgical cytoreduction 
is the most important prognostic factor in case of advanced 
ovarian carcinoma [2–5, 7, 10, 17]. A complete cytoreduc-
tion shoud be the aim of every operation, and if this is 
not possible, the aim should be a minimal residual disease 
[10–16]. Owing to modern surgical techniques, it is possible 
to perform a multivisceral resection in patients with a large 
volume tumor and stage IV disease [5, 17]. Data provided 
in literature suggest, that women operated by gynecologic 
oncologists and surgical oncologists have a much greater 
survival rate compared to the one of patients operated by 
general gynecologists and surgeons without oncologic in-
struction [26]. Our material comprises operations performed 
by a team of oncologic and gynecologic surgeons. This 
has increased the opportunities to use surgical techniques 
Table 2. Postoperative complications 
Duration of operation (min) 90–125 (112)
Perioperative blood unit transfusion 36
Transfused blood unit 
Anastomotic stoma 9
Post-operative bleeding 3
Gastrointestinal obstruction recurrence or occurrence of obstruction as primary symptom of pancreatitis 39
Pancreatitis 3
Period of hospitalization (days) 10–34 (13)
Patients requiring intensive postoperative care (days) 2
Table 3. General medical complications
Perioperative complications Early postoperative complications Late postoperative complications
Respiratory
Exudates (13) Pneumonia 
Pneumonia (8) 6
Cardiovascular
Myocardial infraction (2) Circulatory collapse (7)
Hematological 
Anemia (11) Anemia (17) Deep venous thrombosis (2)
Intestinal
Pancreatitis (2) Ileus (16)
Anastomotic dehiscence (5)
Infections 
Abdominal abscess (3) Abdominal abscess (2)
Eventration (5)
Suppurative lesions (12)
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that not only eliminate the cause of a n acute abdominal 
disease, but also allow to perform cytoreductive surgery. 
Also, owing to this, the number of strictly palliative and 
comfort-reducing operations has been greatly reduced, for 
example such which are due to stomas. The most frequent 
complication occurring in a advanced ovarian carcinoma is 
a gastrointestinal obstruction. It requires emergency surgery 
— an additional negative postoperative prognostic factor. 
The rectosigmoid, because of its continuity, is compressed 
most often and infiltrated by the tumor [18–23]. If this is 
the unique obstruction–causing section of the gastroin-
testinal tract, we assume a two-stage procedure. During 
the first stage, we implant a self-expanding stent to debulk 
the obstruction and to restore anatomic conditions; then, 
after 5 to 7 days, we perform a resection. Gastrointestinal 
debulking by implanting the stent also presents another 
advantage: the number of debulking stomas has been prac-
tically reduced to the situations, where a stent implant is not 
feasible technically. No large studies exist on the subject of 
the presented procedural model regarding a gastrointestinal 
obstruction due to a gynecologic cancer. For example, in 
a situation where such a complication is lacking, Morton 
et al. [18] have retrospectively assessed 58 patients who 
underwent an myometrial resection in conjunction with 
the rectosygmoid. They restored gastrointestinal continu-
ity in all patients. One patient underwent a colostomy due 
to an anastomotic leak, and 3 patients underwent pelvic 
abscess drainage. Similar results were obtained by Peiretti 
et al. [24], where after a surgical resection due to an ovar-
ian cancer with rectosigmoid infiltration and a restoration of 
the gastrointestinal continuity in 238 patients, anastomotic 
leaks occurred in 7 patients, and a pelvic abscesses in 9. In 
our material, anastomotic stomas occurred in 9 patients, 
while the most frequent early complication was a recur-
rence of intestinal obstruction. It occurred in 39 patients and 
caused rehospitalization. In this group of patients, in most 
cases a palliative treatment alleviated obstruction symp-
toms, however a general emaciation due to malnutrition and 
and neoplastic cachexia resulted in 7 deaths. In this group 
of patients, obstruction symptoms were due to a multilevel 
infiltration of the small intestine and colon. According to 
Jaeger et al. [28], in case of an advanced carcinoma compris-
ing the intestines, a multilevel resection will not significantly 
improve the results, despite residual disease resection. How-
ever, most authors [14, 20, 23, 26] affirm in their works, that 
these multivisceral resections indeed improve treatment 
results in patients. A very difficult group of patients as far 
as the extent of surgery is concerned, are patients with 
gastrointestinal perforation and gastrointestinal bleeding. 
In these groups of patients, surgery — often very extensive 
and not due to the carcinoma — is extremely taxing and 
hazardous, but indispensable to save their lives. An optimal 
cytoreduction in these patients is reserved for a narrow 
group where the assessment of the operative risk does not 
exceed ASA II. In our material, 9 patients were operated due 
to gastrointestinal bleeding. Out of them, 6 qualified for ad-
juvant therapy. Cytoreduction was performed in 3 patients 
only. The reason was a preoperative hemorrhagic shock 
and its possible deepening during cytoreductive surgery. 
In our study involving 118 patients, 25 of them (21.2%) 
had not qualified for systemic treatment. The most frequent 
causes were: intestinal obstruction (16 patients); cardiovas-
cular failure (7patients) and massive thrombosis (2 patients). 
93 patients (78.8%) qualified for further treatment. Deaths 
recorded were 3 (2.5%). 39 patients were rehospitalized 
within 30 days. The most frequent cause was neoplastic 
cachexia, impossibility of oral nutrition (without surgical 
cause) and symptoms of a cancer-induced sub-obstruction 
defined as “peritonitis carcinomatosa”. Deaths recorded in 
this group were 7, that is 18% of patients. 
Summing up, it must be said that an aggressive sur-
gical treatment in respect to patients with an advanced 
ovarian cancer implicating an acute abdominal disease is 
a controversial procedure. Controversies center around the 
lack of a uniform procedural scheme in respect to this group 
of patients. The traditional surgical procedure consisting 
only of a local treatment of acute abdominal disease is 
not an appropriate one in respect to the entire group of 
patients and it should be reserved for two oncologically op-
posite groups of patients. The first group comprises patients 
without residual disease in the abdominal cavity, while the 
second those patients who display a technical possibility 
to perform a cytoreduction during emergency surgery. It 
seems that the extent of surgery in this group of patients 
is not determined by the advancement of the carcinoma, 
but by the general condition of the patient, assessed on 
the basis of the advancement of accompanying internal 
diseases. This is confirmed by the results of our work, where 
out of 118 patients, 79 (66.7%) underwent adjuvant therapy 
without surgical complications and rehospitalization. 
CONCLUSIONS 
Combining lifesaving surgery with cytoreduction pro-
vides an opportunity for further adjuvant treatment. Early 
rehospitalization within 30 days is related to an increased 
mortality rate. 
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